期刊文献+

靶向表皮生长因子受体Ⅲ型突变体的第三代嵌合抗原受体的构建与表达 被引量:5

Construction and expression of a third generation chimeric antigen receptor target epidermal growth factor receptor variant Ⅲ-specific
下载PDF
导出
摘要 目的:构建第三代靶向表皮生长因子受体Ⅲ型突变体(EGFRvⅢ)的嵌合抗原受体表达载体,为肿瘤过继免疫治疗提供实验基础。方法:运用分子克隆方法将嵌合抗原受体的胞外抗原结合区(EGFRvⅢ单克隆抗体的轻链和重链可变区,EGFRvⅢsc Fv,726 bp)、铰链区/穿膜区(213 bp)、共刺激分子(CD28和CD137的胞内信号区,123 bp和126 bp)和免疫受体酪氨酸活化基序(CD3ζ链,336 bp)连接成EGFRvⅢsc Fv-CD28-CD137-CD3ζ(EGFRvⅢ/3CAR),克隆入真核表达载体p CDHCMV-MCS-EF1-cop GFP的EcoRⅠ和Bam HⅠ位点,转染293T细胞48 h后提取蛋白,采用SDS-PAGE和Western blotting检测EGFRvⅢ/3CAR的表达。结果:EGFRvⅢsc Fv和基因合成的CD28-CD137-CD3ζ表达框通过重叠延伸PCR拼接成EGFRvⅢ/3CAR,限制性内切酶片段分析和DNA测序均验证了重组载体序列完全正确,Western blotting应用抗人-CD3ζ抗体检测到EGFRvⅢ/3CAR在293T细胞中的完整表达(相对分子质量约58 k D)。结论:成功构建嵌合抗原受体EGFRvⅢ/3CAR表达载体,为嵌合抗原受体修饰T细胞靶向治疗肿瘤提供研究基础。 Objective: To design and construct a vector expressing a human epidermal growth factor receptor variant Ⅲ( EGFRvⅢ)-specific third generation chimeric antigen receptor( CAR) for potential use in adoptive immunotherapy of cancer. Methods: An anti-EGFRvⅢ CAR,referred to as EGFRvⅢ /3CAR,comprising the variable fragment( EGFRvⅢsc Fv),hinge region /transmembrane region,CD28 & CD137 intracellular signal region,and CD3ζ chain of a monoclonal antibody against human EGFvⅢ was generated and inserted in frame into p CDH-CMV-MCS-EF-cop GFP EcoR1 and Bam H1 sites. The integrity of the resultant recombinant vector was confirmed by restriction enzyme mapping and sequence analysis. For further functional integrity verification,the recombinant vector was transfected into 293 T cells and the fusion protein expression was assessed by Western blotting. Results: DNA sequencing and restriction enzyme mapping demonstrated the sequence of EGFRvⅢ /3CAR was corret. Western blotting detected EGFRvⅢ /3CAR protein at approximately58 k D in 293 T cells transfected with the EGFRv Ⅲ /3CAR construct. Conclusion: We have successfully designed and constructed a recombinant vector expressing a human EGFRvⅢ-specific third generation CAR,which may prove usefull in further studies on CAR-based cancer immunotherapy.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2015年第5期603-606,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.81172415) 国家卫计委科研基金资助项目(No.201301010)~~
关键词 嵌合抗原受体 过继免疫肿瘤治疗 表皮生长因子受体Ⅲ型突变体 chimeric antigen receptor adoptive tumor immunotherapy EGFRvⅢ
  • 相关文献

参考文献13

  • 1Kochenderfer JN,Rosenberg SA.Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol . 2013
  • 2Gupta Puja,Han Shuang-Yin,Holgado-Madruga Marina,Mitra Siddhartha S,Li Gordon,Nitta Ryan T,Wong Albert J.Development of an EGFRvIII specific recombinant antibody. BMC Biotechnology . 2010
  • 3Porter David L,Levine Bruce L,Kalos Michael,Bagg Adam,June Carl H.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Quarterly . 2011
  • 4Laurent Sabbagh,Laura M. Snell,Tania H. Watts.??TNF family ligands define niches for T cell memory(J)Trends in Immunology . 2007 (8)
  • 5Tristen S. Park,Steven A. Rosenberg,Richard A. Morgan.Treating cancer with genetically engineered T cells[J]. Trends in Biotechnology . 2011 (11)
  • 6Hiroshi Fujiwara.??Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors(J)International Journal of Hematology . 2014 (2)
  • 7王艺,赵颖颖,韩双印.基于嵌合抗原受体修饰T细胞的肿瘤免疫治疗新策略[J].中国肿瘤生物治疗杂志,2013,20(4):383-390. 被引量:9
  • 8Han EQ,Li XL,Wang CR,Li TF,Han SY.Chimeric antigen receptor-engineered T cells for cancer immunotherapy:progress and challenges. J Hematol Oncol . 2013
  • 9Finney HM,Akbar AN,Lawson AD.Activation of resting human primary T cells with chimeric re-ceptors:costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol . 2004
  • 10Johnson LA,Scholler J,Ohkuri T,et al.Rational development and characterization of humanized anti-EGFR variantⅢchimeric antigen receptor T cells for glioblastoma. Sci Transl Med . 2015

二级参考文献50

  • 1张瑞萍,云琳,陆斌,彭玲,周倩,王浩,郭亚军.嵌合T细胞受体的构建及其在T淋巴细胞表面的表达和体外抗肿瘤功能的检测[J].中华实验外科杂志,2006,23(5):609-611. 被引量:3
  • 2Schreiber RD, Old U, Smyth MJ. Cancer immunoediting: In-tegrating immunity ’ s roles in cancer suppression and promotion[J]. Science,2011,331(6024) : 1565-1570.
  • 3Cheadle EJ,Sheard V,Hombach AA, et al. Chimeric antigen re-ceptors for T-cell based therapy [ J]. Methods Mol Biol, 2012,907: 645-666.
  • 4Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell trans-fer: A clinical path to effective cancer immunotherapy [ J] . NatRev Cancer, 2008, 8(4) : 299-308.
  • 5Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subsetwith stem cell-like properties [ J]. Nat Med,2011,17 (10 ):1290-1297.
  • 6Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cellreceptor chimeric molecules as functional receptors with antibody-type specificity [ J]. Proc Natl Acad Sci U S A, 1989, 86(24):10024-10028.
  • 7Ahmed N, Ratnayake M, Savoldo B,et al. Regression of experi-mental medulloblastoma following transfer of HE R2-specific Tcells [J]. Cancer Res, 2007, 67(12) : 5957-5964.
  • 8Chmielewski M, Hahn 0,Rappl G, et al. T cells that target car-cinoembryonic antigen eradicate orthotopic pancreatic carcinomaswithout inducing autoimmune colitis in mice [ J]. Gastroenterolo-gy, 2012, 143(4) :1095-1107.
  • 9Guest RD, Hawkins RE,Kirillova N,et al. The role of extracel-lular spacer regions in the optimal design of chimeric immune re-ceptors :Evaluation of four different scFvs and antigens [ J]. JImmunother, 2005,28(3) : 203-211.
  • 10Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigenresponse of chimeric antigen receptors harboring the CD3zetatransmembrane domain is dependent upon incorporation of the re-ceptor into the endogenous TCR/CD3 complex [ J]. J Immunol,2010, 184(12) : 6938-6949.

共引文献9

同被引文献27

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部